ArticleMolecular psychiatry2026
Delay discounting correlates with depression but does not predict relapse after antidepressant discontinuation.
Article in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Neural Markers of Reward Valuation and Impulsive Decision-Making in Mania Risk.JAMA psychiatry · 2026Article
- Delay discounting correlates with depression but does not predict relapse after antidepressant discontinuation.Molecular psychiatry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Approximately one third of people with Major Depressive Disorder (MDD) experience a relapse within six months of discontinuing antidepressant medication (ADM), however, reliable predictors of relapse following ADM discontinuation are currently lacking. A putative behavioural predictor is delay discounting, which measures a person's impatience to receive reward. Previous studies have linked delay discounting to both MDD and reduced serotonergic function, rendering it a plausible candidate predictor. In this multi-site study we measured delay discounting in participants with remitted MDD (N = 97), before and within six months after discontinuation of ADM, and in matched controls without a lifetime history of MDD (N = 54). Using predictive models, we tested whether either baseline discounting, or an early change in discounting following ADM discontinuation, predicted depressive relapse over a six month follow up period. We also tested differences between remitted MDD and control groups in delay discounting at baseline, and associations between discounting and depressive symptoms. We found that the remitted MDD group, compared to the control group, showed significantly higher (p < 0.05; Cohen's d = 0.34) discounting at baseline. In addition, baseline discounting was positively correlated with depression rating scores (Spearman ρ = 0.24). However, delay discounting did not increase following ADM discontinuation. Neither baseline discounting, nor a change in discounting following ADM discontinuation, predicted subsequent depressive relapse. We conclude that delay discounting is elevated in remitted MDD treated with antidepressant medication. However, delay discounting neither increases following ADM discontinuation, nor does it prospectively predict depressive relapse. These results suggest that delay discounting in Major Depressive Disorder has little relationship with illness trajectory following ADM discontinuation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.